Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA
Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA


Pfizer Inc. (NYSE: PFE) today shared data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients) study evaluating the use of PAXLOVID™ (nirmatrelvir

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610)

LivaNova Elects Peter Wilver to Board of Directors
LivaNova Elects Peter Wilver to Board of Directors


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Peter Wilver has been elected to the Board of Directors, effective immediately. His election

DGAP-News: MicroVision to Showcase its Automotive Lidar Sensor at ADAS & Automotive Technology Expo in Stuttgart, Germany
DGAP-News: MicroVision to Showcase its Automotive Lidar Sensor at ADAS & Automotive Technology Expo in Stuttgart, Germany
DGAP-News: MicroVision to Showcase its Automotive Lidar Sensor at ADAS & Automotive Technology Expo in Stuttgart, Germany
Humana to Donate Downtown Louisville Office Building to UofL
Humana to Donate Downtown Louisville Office Building to UofL


Humana Inc. (NYSE: HUM) today announced that it will donate an office building in Downtown Louisville to the University of Louisville (UofL) in support of the activities of UofL’s Health Equity

Come Chill at Dexcom’s ‘No Pricks Parlour’ With Ed Gamble for Diabetes Awareness Week, Celebrating You!
Come Chill at Dexcom’s ‘No Pricks Parlour’ With Ed Gamble for Diabetes Awareness Week, Celebrating You!


Come chill with us! This week is Diabetes Awareness Week and DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (rt-CGM) for people with diabetes, is honouring

Come Chill at Dexcom’s ‘No Pricks Parlour’ With Ed Gamble for Diabetes Awareness Week, Celebrating You!
Come Chill at Dexcom’s ‘No Pricks Parlour’ With Ed Gamble for Diabetes Awareness Week, Celebrating You!


Come chill with us! This week is Diabetes Awareness Week and DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (rt-CGM) for people with diabetes, is honouring

DGAP-News: Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting
DGAP-News: Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting
DGAP-News: Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital


Regulatory News:



Nanobiotix (Paris:NANO) (NASDAQ:NBTX)
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: w

Pfizer Completes Acquisition of ReViral
Pfizer Completes Acquisition of ReViral


Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and

Pfizer Completes Acquisition of ReViral
Pfizer Completes Acquisition of ReViral


Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research

Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041
Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041


POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines:
Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines


Agilent Technologies Inc. (NYSE: A), a global leader in genomics technology, today announced it will use Amazon Elastic Compute Cloud (Amazon EC2) G5g instances powered by Amazon Web Services (AWS)

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced

Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.


Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling

Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.


Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling

GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older


GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of

GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older


GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase II SUMMIT trial, assessing the efficacy of combined neratinib, fulvestrant, and trastuzumab in

Agilent Announces New Oligonucleotide Analysis Software for Biopharma Research
Agilent Announces New Oligonucleotide Analysis Software for Biopharma Research


Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent high-resolution LC/MS for oligonucleotide